Applied Therapeutics appointed John H. Johnson as Executive Chairman and Les Funtleyder as interim CEO, while Dr. Shoshana Shendelman stepped down, receiving a $2.1 million severance package; the company also plans to submit a new drug application for govorestat after Q1 2025.